Local delivery of antineoplastic agents using biodegradable polymers for the treatment of malignant brain tumors

References

• Legler LM, Gloeckler Ries LA, Smith MA et al Brain and other central nervous system cancers: Recent trends in incidence and mortality.' Natl. Cancerinst. 91(16), 1382–1390 (1999).
   Google Scholar
• Rostomily R, Keles GE, Berger MS. Radical surgery in the management of low-grade and high-grade gliomas. Bailiieres Clin. Neural. 5(2), 345–369 (1996).
   Google Scholar
• Chang CH, Horton J, Schoenfeld D et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern co-operative oncology group study. Cancer Res. 52(6), 997–1007 (1983).
   Google Scholar
• Green SB, Byar DP, Walker MD et al Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Brat. Rep. 67(2), 121–132 (1983).
   Google Scholar
• Kornblith PL, Walker M. Chemotherapy for malignant gliomas. I Neurosurg. 68(1), 1–17 (1988).
   Google Scholar
• Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl. I Med. 303(23), 1323–1329 (1980).
   Google Scholar
• Walker MD, Alexander EJ, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A co-operative clinical trial. J. Neurosurg. 49(3), 333–343 (1978).
   Google Scholar
• Barker FG, Chang SM, Gutin PH et al Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42(4), 709–720 (1998).
   PubMed Web of Science ®Google Scholar
• Mohan DS, Suh JH, Phan JL et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary institution. Int. J. Rad. Oncol. Biol. Phys. 42(5), 981–987 (1998). toRubin LL, Staddon JM. The cell biology of the blood—brain barrier. Ann. Rev Neurosci. 22, 11–28 (1999).
   Google Scholar
• Igarashi Y, Utsumi H, Chiba H et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood—brain barrier. Biochem. Biophys. Res. Commun. 261 (1), 108–112 (1999).
   Google Scholar
• Rowland LPFM, Rubin L. Cerebrospinal fluid: Blood—brain barrier, brain edema and hydrocephalus. In: Principles of Neural Science. Kandel ERSJ, Jessel TM, (Eds). Elsevier, NY, USA, 1050–1060 (1991).
   Google Scholar
• Pardridge WM. Vector-mediated drug delivery to the brain. Adv. Drug Deliv. Rev 36(2–3), 299–321 (1999).
   Google Scholar
• Williams PC, Henner WD, Roman-Goldstein S et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the 543 blood—brain barrier in the treatment of intracranial neoplasms. Neurosurgery 37(1), 17–28 (1995).
   Google Scholar
• Hochberg F, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neumlogy30, 907–911 (1980).
   PubMed Web of Science ®Google Scholar
• Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 263,797–800 (1976).
   PubMed Web of Science ®Google Scholar
• Tamargo R, Brem H. Drug delivery to the central nervous system: a review. Neurosurgery Quarterly2 (4), 259–279 (1992).
   Google Scholar
• Leong KW Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation and release characteristics. J. Blamed. Mater. Res. 19(8), 941–955 (1985).
   Google Scholar
• Chasm n M, Domb A, Ron E. Polyanhydrides as drug delivery systems. In: Biodegradable Polymers as Drug Delivery Systems. Chasm n M, Langer R, (Eds). Marcel Dekker, NY, USA, 43–70 (1990).
   Google Scholar
• Langer R, Run H, Tapper D. Biocompatibility of polymeric delivery systems for macromolecules.' Blamed. Mater Res. 15(2), 267–277 (1981).
   Google Scholar
• Brem H, Kader A, Epstein JI et al Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel. Cancer Ther: 5(2), 55–65 (1989).
   PubMedGoogle Scholar
• Tamargo RJ, Epstein JI, Reinhard CS, Chasm n M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J. Blamed. Miter. R. 23(2), 253–266 (1989).
   Google Scholar
• Brem H, Tamargo RJ, Olivi A et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg. 80(2), 283–290 (1994).
   PubMed Web of Science ®Google Scholar
• Shieh L, Tamada J, Chen I et al Erosion of a new family of biodegradable polyanhydrides. j Blamed. Mater Res. 28(12), 1465–1475 (1994).
   PubMed Web of Science ®Google Scholar
• Olivi A, Ewend MG, Utsuki T et a/. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Tharmacol. 39(1–2), 90–96 (1996).
   Google Scholar
• Judy KD, Olivi A, Buahin KG et al Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. I Neurosurg. 82(3), 481–486 (1995).
   Google Scholar
• Kong Q, Kleinschmidt-Demasters BK, Lillehei KO. Intralesionally implanted cisplatin cures primary brain tumor in rats. Surg. Oncol 64(4), 268–273 (1997).
   Web of Science ®Google Scholar
• Lillehei KO, Kong Q, Withrow SJ, Kleinschmidt-Demasters BK. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 91 gliosarcoma in the rat. Neurosurgery39(6), 1191–1199 (1996).
   Google Scholar
• Menei P, Daniel V, Montero-Menei C et al Biodegradation and brain tissue reaction to poly(d,l-lactide-coglycolide) microspheres. Biomaterials 14 (6), 470–478 (1993) .
   PubMed Web of Science ®Google Scholar
• Spenlehauer G, Vert M, Benoit JP, Boddaert A. In vitro and in vivo degradation of poly(d,llactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials10(8), 557–563 (1989).
   PubMed Web of Science ®Google Scholar
• Sato H, Wang YM, Adachi I, Horikoshi I. Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol. Pharm. Bull. 19(12), 1596–1601 (1996).
   Google Scholar
• Peyman GA, Conway M, Khoobehi B, Soike K. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol 16(2), 109–113 (1992).
   Google Scholar
• Williams RC, Paquette DW, Offenbacher S et al Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. Periodontal. 72(11), 1535–1544 (2001).
   Google Scholar
• Sugiyama T, Kumagai S, Nishida T et al Experimental and clinical evaluation of cisplatin-containing microspheres as ip. chemotherapy for ovarian cancer. Anticancer Res. 18(4B), 2837–2842 (1998) .
   Google Scholar
• Menei P, Benoit JP, Boisdron-Celle M et al Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neumsurgery 34(6), 1058–1064 (1994).
   PubMed Web of Science ®Google Scholar
• Brem H, Langer R. Polymer-based drug delivery to the brain. Li. Med. July/August, 52–61 (1996).
   Google Scholar
• Oda Y, Tokuriki Y, Tsuda E, Handa H, Kieler J. Trial of anticancer pellet in malignant brain tumours; 5 fu and urokinase embedded in silastic. Acta Neurochir. Suppl 28(2), 489–490 (1979) .
   Google Scholar
• Oda Y, Uchida Y, Murata T et al Treatment of brain tumors with anticancer pellet-experimental and clinical study. Na. Shinkei. Geka. 10(4), 375–381 (1982).
   Google Scholar
• Oda Y, Kamijyo Y, Okumura T et al Clinical application of a sustained release anticancer pellet. Na. Shinkei. Geka. 13(12), 1305–1311 (1985).
   Google Scholar
• Kik) O, Himuro H, Inoue N et al Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites. Shinkei. Geka. 14(10), 1189–1195 (1986).
   PubMedGoogle Scholar
• Grossman SA, Reinhard C, Colvin OM et al The intracerebral distribution of bcnu delivered by surgically implanted biodegradable polymers. I Neurosurg: 76(4), 640–647 (1992).
   PubMed Web of Science ®Google Scholar
• Fung LK, Ewend MG, Sills A et a/. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer ReK 58(4), 672–684 (1998).
   Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI et al Interstitial chemotherapy of the 91 gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 53(2), 329–333 (1993).
   Google Scholar
• Galicich JH, Sundaresan N, Thaler HT. Surgical treatment of single brain metastasis. Evaluation of results by computerized tomography scanning. Neumsurg 53(1), 63–67 (1980).
   Google Scholar
• Brem H, Mahaley MS Jr, Vick NA et al Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. I Neurosurg: 74(3), 441–446 (1991).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345(8964), 1008–1012 (1995).
   PubMedGoogle Scholar
• Brem H, Ewend MG, Piantadosi S et al The safety of interstitial chemotherapy with bcnu-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. Neurooncol 26(2), 111–123 (1995).
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P et al Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neumsurgery 41(1), 44–48 (1997).
   PubMed Web of Science ®Google Scholar
• Westphal MHD, Bortey E, Delavault P et al A Phase 3 trial of local chemotherapy with biodegradable carmustine (bcnu) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol 5, (2003).
   Google Scholar
• Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of bcnu from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol 39(5), 383–389 (1997).
   Google Scholar
• Olivi A GS, Tatter S, Barker PG et al Results of a Phase I dose escalation study using bcnu impregnated polymers in patients with recurrent malignant gliomas. Clin. Oncol (In Press).
   Google Scholar
• Silber JR, Bobola MS, Ghatan S et al 06- methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58(5), 1068–1073 (1998).
   Google Scholar
• Pegg AE, Boosalis M, Samson L et al Mechanism of inactivation of human o6-alkylguanine-DNA alkyltransferase by o6-benzylguanine. Biochemistry 32 (45), 11998–12006 (1993).
   Google Scholar
• Rhines LD, Sampath P, Dolan ME et al Ci-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 60 (22), 6307–6310 (2000).
   Google Scholar
• Cahan MA, Walter IKA, Colvin OM, Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol 33(5), 441–444 (1994).
   Web of Science ®Google Scholar
• Klecker R, Jamis-Dow C, Egorin M. Distribution and metabolism of 3-h taxol in the rat. Proc. Am. Assoc. Cancer Res. 34, 381 (1992).
   Google Scholar
• Walter IKA, Cahan MA, Gur A et al Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 54(8), 2207–2212 (1994).
   Google Scholar
• Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer 7i-eat. Rep. 65 (Suppl. 3), 89–95 (1981).
   Google Scholar
• Buahin KG, Judy KD, Hartke C et al Controlled release of 4- hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid co-polymer. Polym. Adv. Technol 3,311(1993).
   Google Scholar
• Goodman LS, Hardman JG, Limbird LE, Gilman AG. Goodman and Gilmanis the Pharmacological Basis of Therapeutics. 10th Edition. McGraw-Hill, NY, USA, 2148 (2001).
   Google Scholar
• Boisdron-Celle M, Menei P, Benoit JR Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. Pharmacol 47(2), 108–114 (1995).
   Google Scholar
• Menei P, Boisdron-Celle M, Croue A, Guy G, Benoit JR Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and c6 glioma-bearing rats. Neurosurgery 39(1), 117–124 (1996).
   Google Scholar
• Menei P, Venier MC, Gamelin E et al Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer86(2), 325–330 (1999).
   Google Scholar
• •Excellent overview of a Phase I clinical trial for the treatment of malignant brain tumors.
   Google Scholar
• Brem H, Lawson H. The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86 (2), 197–199 (1999) .
   PubMed Web of Science ®Google Scholar
• Lin SY, Lui WY, Chen CF, Han SH. Tumoricidal effect of controlled-release polymeric needle devices containing adriamycin HCL in tumor-bearing mice. Biomater. Az-tif Cells Artif Organs17(2), 189–203 (1989).
   PubMed Web of Science ®Google Scholar
• Watts MC, Lesniak MS, Burke M et al Controlled release of adriamycin in the treatment of malignant glioma. American Association of Neurological Surgeons Annual Meeting, Denver, CO, USA (1997).
   Google Scholar
• Gaynon P, Ettinger L, Baum E et al Carboplatin in childhood brain tumors. A children's cancer study group phase II trial. Cancer66, 2465–2469 (1990).
   Google Scholar
• Hannigan E, Green S, Alberts D, O'Toole R, Surwit E. Results of a southwest oncology group phase II trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50\(Suppl. 2), 2–9 (1993).
   Google Scholar
• Doz F, Berens M, Dougherty D, Rosenblum M. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. Neurooncolll, 27–35 (1991).
   Google Scholar
• Olivi A, Gilbert M, Duncan K et al. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother Pharmacol 31(6), 449–454 (1993).
   PubMed Web of Science ®Google Scholar
• Olivi A, Ewend M, Utsuki T et al Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Pharmacol 39(1-2), 90–96 (1996).
   Web of Science ®Google Scholar
• Utsuki T, Brem H, Pitha J et al. Potentiation of anticancer effects of microencapsulated carboplatin by hydroxypropyl a-cyclodextrin. J. Controlled Release 40,251–260 (1996).
   Web of Science ®Google Scholar
• Hsiang YH, Liu LE Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48(7), 1722–1726 (1988).
   Google Scholar
• Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85(4), 271–291 (1993).
   Google Scholar
• Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 91 gliosarcoma model. int. Cancer 62 (5), 605–609 (1995) .
   Google Scholar
• DiMeco F, Li KW, Tyler BM et al. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J. Neurosurg. 97(5), 1173–1178 (2002).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl. I Med. 285(21), 1182–1186 (1971)
   Google Scholar
• Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. I EAp. Med. 136(2), 261–276 (1972).
   Web of Science ®Google Scholar
• Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221(4612), 719–725 (1983).
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Leong KW, Brem H. Growth inhibition of the 91 glioma using polymers to release heparin and cortisone acetate. J. Neurooncol 9(2), 131–138 (1990).
   Google Scholar
• Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51(2), 672–675 (1991).
   PubMed Web of Science ®Google Scholar
• Sills AK Jr, Williams JI, Tyler BM et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 58(13), 2784–2792 (1998).
   Google Scholar
• Bhargava P, Marshall JL, Dahut W et al A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin. Cancer Res. 7(12), 3912–3919 (2001).
   PubMed Web of Science ®Google Scholar
• Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Collagen xviii/endostatin structure and functional role in angiogenesis. Cell Struct. Funct. 25(2), 97–101 (2000).
   Google Scholar
• O'Reilly MS, Boehm T, Shing Y et al Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Ce1188(2), 277–285 (1997).
   Google Scholar
• ••Excellent article describing the potentantiangiogenesis activity of endostatin.
   Google Scholar
• Kim YM, Jang JW, Lee OH et a/. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix met alloproteinase. Cancer Res. 60 (19), 5410–5413 (2000).
   PubMed Web of Science ®Google Scholar
• Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits c6 glioma growth. int. j Cancer 97(6), 839–845 (2002).
   Google Scholar
• Thompson RC, Pardoll DM, Jaffee EM et al Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. Immunother. Emphasis Tumor Immunol 19(6), 405–413 (1996).
   PubMed Web of Science ®Google Scholar
• Ewend MG, Thompson RC, Anderson R et al Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. I Immunother 23(4), 438–448 (2000).
   Google Scholar
• Hanes J, Suh K, Tyler B et al. Local interleukin-2 delivery eradicates brain and liver tumors. From the Proceedings of the International Symposium of Control Relative Bioactive Materials. Las Vegas, NV, USA (1998).
   Google Scholar
• DiMeco F, Rhines LD, Hanes J et al Paracrine delivery of IL-12 against intracranial 91 gliosarcoma in rats. Neurosurg. 92(3), 419–427 (2000).
   Google Scholar
• Sampath P, Hanes J, DiMeco F et al Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59(9), 2107–2114 (1999).
   Google Scholar
• •The autors demonstrate how combination chemotherapy and immunotherapy can lead to a synergistic response against experimental brain tumors.
   Google Scholar
• Rhines LD, DiMeco F, Lawson HC et al Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery52 (4), 872–880 (2003) .
   Google Scholar
• Bobo RII, Laske DW, Akbasak A et al Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Li. USA 91(6), 2076-2080 (1994).
   Google Scholar
• Laske DW, Morrison PF, Lieberman DM et al Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. Neurasurg 87(4), 586–594 (1997).
   PubMed Web of Science ®Google Scholar
• Lieberman DM, Corthesy ME, Cummins A, Oldfield EH. Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. Neurosurg. 90(5), 928–934 (1999).
   Google Scholar
• Lonser RR, Corthesy ME, Morrison PF, Gogate N, Oldfield EH. Convection- enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. I Neurosurg 91(2), 294–302 (1999).
   PubMed Web of Science ®Google Scholar
• •Excellent article which describes the use of convection-enhanced drug delivery in the treatment of parkinsonian symptoms.
   Google Scholar
• Santini JT Jr, Cima MJ, Langer R. A controlled-release microchip. Nature 397(6717), 335–338 (1999).
   PubMed Web of Science ®Google Scholar
• ••Describes a novel approach to drugdelivery Shows how a solid state silicon chip may have the potential to deliver multiple drugs at different time points. Affiliations
   Google Scholar